Food and Drug Administration

Psychopharmacologic Drugs Advisory Committee

March 23, 2006

Briefing Information

Cephalon, Inc.     

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Modafinil (CEP-1538) Tablets

FDA

Disclaimer

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. §552).
These redacted portions will appear as white space on the screen or on the printed page.

Briefing Information

FDA

 

FDA Table of Contents